NCT02907996

Brief Summary

The objectives of this study are to collect and assess data related to safety and effectiveness of Sovaldi treatment regimens, per the approved prescribing information for Sovaldi, in routine clinical practice and report results to Korean Ministry of Food and Drug Safety (MFDS).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,033

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2016

Longer than P75 for all trials

Geographic Reach
1 country

72 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 9, 2016

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

September 16, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 20, 2016

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 9, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 9, 2021

Completed
Last Updated

December 27, 2021

Status Verified

December 1, 2021

Enrollment Period

5.3 years

First QC Date

September 16, 2016

Last Update Submit

December 23, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Percentage of Participants Experiencing Any Adverse Events (AEs) Occurring During Administration of Sovaldi Regimens or Within 30 Days After Completion (or Discontinuation) of Sovaldi Treatment Regimens

    First dose date up to 30 days posttreatment

  • Proportion of Participants with HCV RNA < Lower Limit of Quantification (LLOQ)

    2 weeks before Posttreatment Week 12 through Week 24 Posttreatment

Secondary Outcomes (1)

  • Percentage of Participants Experiencing Any AEs Occurring During Administration of Sovaldi Regimens or Within 12 Weeks After Completion (or Discontinuation) of Sovaldi Treatment Regimens

    First dose date up to 12 weeks posttreatment

Study Arms (1)

Sofosbuvir

Adult Korean participants with genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean participants aged 12 to \<18 years with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens

Drug: Sofosbuvir

Interventions

400 mg tablet administered orally once daily

Also known as: Sovaldi ®
Sofosbuvir

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult Korean individuals with Genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean individuals (aged 12 to \<18 years) with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens.

You may qualify if:

  • Individuals aged 12 years and older who are living in Korea
  • Individuals with chronic HCV infection eligible for treatment with Sovaldi as indicated in the approved prescribing information for Sovaldi
  • Individuals who have been informed of all pertinent aspects of the study and have voluntarily signed Personal Information Protection Act (PIPA) consent form; Pediatric individuals who have their legally authorized representatives sign the PIPA consent form

You may not qualify if:

  • Individuals treated with Sovaldi outside of the approved prescribing information for Sovaldi in Korea
  • Individuals who have a contra-indication (refer to the Korea prescribing information)
  • Individuals who have a contra-indication to ribavirin or peginterferon alfa or daclatasvir
  • Pregnant or breast feeding women
  • Individuals who have previously been administered Sovaldi
  • Individuals participating in a concurrent HCV clinical trial
  • Individuals planning on leaving the country during the study period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (72)

Yonsei University Wonju Severance Christian Hospital

Wŏnju, Gangwon-do, 26426, South Korea

Location

CHA Bundang Medical Center

Sungnam, Gyeonggi-d, 463-712, South Korea

Location

Hallym University Sacred Heart Hospital

Anyang, 14068, South Korea

Location

The Catholic University of Korea Bucheon ST. Mary's Hospital

Bucheon-si, 14647, South Korea

Location

SoonChunHyang University Bucheon Hospital

Bucheon-si, 420-767, South Korea

Location

Inje University Haeundae Paik Hospital

Busan, 48108, South Korea

Location

BongSeng Memorial Hospital

Busan, 48775, South Korea

Location

Dong-A University Hospital

Busan, 49201, South Korea

Location

Pusan National University Hospital

Busan, 49241, South Korea

Location

Kosin University Gospel Hospital

Busan, 49267, South Korea

Location

Inje University Busan Paik Hospital

Busan, 614-735, South Korea

Location

Busan St. Mary's Hospital

Busan, South Korea

Location

Busan Veterans Hospital

Busan, South Korea

Location

Maryknoll Medical Center

Busan, South Korea

Location

Changwon Fatima Hospital

Changwon, 51394, South Korea

Location

Dankook University Hospital

Cheonan, 31116, South Korea

Location

SoonChunHyang University Cheonan Hospital

Cheonan, 31151, South Korea

Location

Hallym University ChunCheon Sacred Heart Hospital

Chuncheon, 24253, South Korea

Location

Konkuk University Chungju Hospital

Chungju, 27376, South Korea

Location

Keimyung University Dongsan Medical Center

Daegu, 41931, South Korea

Location

Yeungnam University Medical Center

Daegu, 42415, South Korea

Location

Daegu Catholic University Medical Center

Daegu, 42472, South Korea

Location

Kyungpook National University Hospital

Daegu, 700-721, South Korea

Location

Kyungpook national university medical center Chil-Gok

Daegu, 700-721, South Korea

Location

DaeJeon ST. Mary's Hospital

Daejeon, 301-723, South Korea

Location

Chungnam National University Hospital

Daejeon, 35015, South Korea

Location

Daejeon Eulji Medical Center

Daejeon, 35233, South Korea

Location

GangNeung Asan Hospital

Gangneung, 25440, South Korea

Location

Dongguk University Ilsan Hospital

Goyang, 10326, South Korea

Location

Myongji Hospital

Goyang, 10475, South Korea

Location

National Health Insurance Cooperation Ilsan Hospital

Goyang-si, 10444, South Korea

Location

Kumi Cha Hospital

Gumi, 39295, South Korea

Location

Hanyang University Guri Hospital

Guri-si, 11923, South Korea

Location

Konkuk University Medical Center

Gwangjin-gu, 05030, South Korea

Location

Chosun University Hospital

Gwangju, 501-717, South Korea

Location

Kwangju Christian Hospital

Gwangju, 61661, South Korea

Location

Dongguk University Gyeongju Hospital

Gyeongju, 38067, South Korea

Location

Hallym University Dongtan Sacred Heart Hospital

Hwaseong-si, South Korea

Location

Chonnam National University Hwasun Hospital

Hwasun, 58128, South Korea

Location

WonKwang University Hospital

Iksan, 54538, South Korea

Location

The Catholic University of Korea, Incheon St. Mary's Hospital

Incheon, 21431, South Korea

Location

Inha University Hospital

Incheon, 22332, South Korea

Location

Catholic Kwandong University International St. Mary's Hospital

Incheon, 22711, South Korea

Location

Gachon University Gil Medical Center

Incheon, 405-760, South Korea

Location

Cheju Halla General Hospital

Jeju City, 63127, South Korea

Location

Presbyterian Medical Center

Jeonju, 54987, South Korea

Location

Chonbuk National University Hospital

Jeonju, South Korea

Location

Gyeongsang National University Hospital

Jinju, 52727, South Korea

Location

Seoul National University Bundang Hospital

Seongnam-si, 13620, South Korea

Location

Korea University Anam Hospital

Seoul, 02841, South Korea

Location

Seoul National University Hospital

Seoul, 03080, South Korea

Location

Kangbuk Samsung Hospital

Seoul, 03181, South Korea

Location

Seoul National University Hospital

Seoul, 03830, South Korea

Location

SoonChunHyang University Hospital

Seoul, 04401, South Korea

Location

Hanyang University Hospital

Seoul, 04763, South Korea

Location

Asan Medical Center

Seoul, 05505, South Korea

Location

Kangdong Sacred Heart Hospital

Seoul, 05535, South Korea

Location

Chung-Ang University Hospital

Seoul, 06973, South Korea

Location

Boramae Medical Center

Seoul, 07061, South Korea

Location

Ewha Womans University Mokdong Hospital

Seoul, 07985, South Korea

Location

Inje University Seoul Paik Hospital

Seoul, 100-032, South Korea

Location

Severance Hospital

Seoul, 120-752, South Korea

Location

Samsung Medical Center

Seoul, 135-710, South Korea

Location

Korea University Guro Hospital

Seoul, 152-703, South Korea

Location

Inje University Sanggye Paik Hospital

Seoul, South Korea

Location

Nowon Eulji Medical Center

Seoul, South Korea

Location

Ajou University Hospital

Suwon, 16499, South Korea

Location

The Catholic University of Korea, St. Vincent's Hospital

Suwon, 41931, South Korea

Location

The Catholic University of Korea Uijeongbu St. Mary's Hospital

Uijeongbu-si, 11765, South Korea

Location

Ulsan University Hospital

Ulsan, 44033, South Korea

Location

Pusan National University Yangsan Hospital

Yangsan, 50612, South Korea

Location

Yongin Severance Hospital

Yŏngin, 17046, South Korea

Location

Related Links

MeSH Terms

Conditions

Hepatitis C

Interventions

Sofosbuvir

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Uridine MonophosphateUracil NucleotidesPyrimidine NucleotidesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsNucleotidesNucleic Acids, Nucleotides, and NucleosidesRibonucleotides

Study Officials

  • Gilead Study Director

    Gilead Sciences

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2016

First Posted

September 20, 2016

Study Start

September 9, 2016

Primary Completion

December 9, 2021

Study Completion

December 9, 2021

Last Updated

December 27, 2021

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations